Business
GenSight Biologics Announces the Closing of the Company’s c. €4 Million Private Placement
PARIS, July 03, 2025--Regulatory News: NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/0d846d77fb8dd2bc5f5af32115e5037b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y7At3mUw0NY0l.C0jAz4pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0d846d77fb8dd2bc5f5af32115e5037b","width":480,"height":204}},"lazy":false},{"type":"text","content":"PARIS, July 03, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA","length":120,"tagName":"p"},{"type":"text","content":"GenSight Biologics (the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the closing of its EUR 3,908,715.39 private placement (the "Private Placement").","length":373,"tagName":"p"},{"type":"text","content":"The Private Placement resulted in the issuance of 21,251,267 ordinary shares of the Company (the "Offered Shares"). The Offered Shares will be admitted to trading on Euronext Paris on July 3, 2025 (ISIN FR0013183985/SIGHT).","length":233,"tagName":"p"},{"type":"text","content":"The issuance of:","length":16,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The 1,850,000 pre-funded warrants (the "Offered Pre-Funded Warrants") giving the right to subscribe to 1,850,000 additional ordinary shares (the "Pre-Funded Warrant Shares"); and","length":198,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The 23,101,267 warrants (the "Offered Investor Warrants") giving the right to subscribe to 23,101,267 additional ordinary shares (the "Investor Warrant Shares")","length":180,"tagName":"p","attribs":{}}]}],"tagName":"ol","bulletedList":false,"length":378},{"type":"text","content":"is expected to take place tomorrow, July 4, 2025.","length":49,"tagName":"p"},{"type":"text","content":"The Offered Investor Warrants will be admitted to trading on the Euronext ...